MX2021006902A - Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica. - Google Patents

Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.

Info

Publication number
MX2021006902A
MX2021006902A MX2021006902A MX2021006902A MX2021006902A MX 2021006902 A MX2021006902 A MX 2021006902A MX 2021006902 A MX2021006902 A MX 2021006902A MX 2021006902 A MX2021006902 A MX 2021006902A MX 2021006902 A MX2021006902 A MX 2021006902A
Authority
MX
Mexico
Prior art keywords
treatment
sup
compounds
prophylaxis
virus infection
Prior art date
Application number
MX2021006902A
Other languages
English (en)
Inventor
Bo Zhang
Lu Gao
Chungen Liang
Hongying Yun
Xiufang Zheng
Jianping Wang
Kun Miao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021006902A publication Critical patent/MX2021006902A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I): (ver Fórmula) (I), en la que R1, R2 y R3 son tal como se indica en la presente memoria y sus profármacos o sal, enantiómero o diastereómero farmacéuticamente aceptable del mismo, y composiciones que incluyen los compuestos y métodos de utilización de los compuestos.
MX2021006902A 2016-08-29 2019-02-21 Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica. MX2021006902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12

Publications (1)

Publication Number Publication Date
MX2021006902A true MX2021006902A (es) 2021-07-07

Family

ID=59738346

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002129A MX2019002129A (es) 2016-08-29 2017-08-28 Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
MX2021006902A MX2021006902A (es) 2016-08-29 2019-02-21 Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019002129A MX2019002129A (es) 2016-08-29 2017-08-28 Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.

Country Status (31)

Country Link
US (3) US10233184B2 (es)
EP (2) EP3865482A1 (es)
JP (2) JP7013467B2 (es)
KR (2) KR20220147702A (es)
CN (1) CN109641904B (es)
AU (3) AU2017320742B2 (es)
BR (1) BR112019003519A2 (es)
CA (1) CA3034148A1 (es)
CL (1) CL2019000512A1 (es)
CO (1) CO2019000932A2 (es)
CR (1) CR20190087A (es)
DK (1) DK3504210T3 (es)
ES (1) ES2867849T3 (es)
HR (1) HRP20210621T1 (es)
HU (1) HUE053944T2 (es)
IL (3) IL293475A (es)
MA (1) MA46038B1 (es)
MX (2) MX2019002129A (es)
MY (1) MY197408A (es)
NZ (1) NZ750604A (es)
PE (1) PE20190476A1 (es)
PH (1) PH12019500432A1 (es)
PL (1) PL3504210T3 (es)
PT (1) PT3504210T (es)
RS (1) RS61752B1 (es)
RU (1) RU2751349C2 (es)
SG (2) SG10202010520SA (es)
SI (1) SI3504210T1 (es)
TW (1) TWI671300B (es)
UA (1) UA124270C2 (es)
WO (1) WO2018041763A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CR20190087A (es) * 2016-08-29 2019-04-30 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica
EP3970750A1 (en) * 2016-09-13 2022-03-23 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
KR20200128414A (ko) * 2018-02-28 2020-11-12 에프. 호프만-라 로슈 아게 간암의 치료 및 예방을 위한 7-치환된 설폰이미도일퓨린온 화합물 및 유도체
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
JP2023514727A (ja) 2020-02-21 2023-04-07 シルバーバック セラピューティックス インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
WO2021177679A1 (ko) 2020-03-02 2021-09-10 성균관대학교산학협력단 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
EP4194006A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
WO2022063278A1 (zh) * 2020-09-27 2022-03-31 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
AUPO912997A0 (en) * 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
KR100613634B1 (ko) * 1997-11-28 2006-08-18 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 복소환 화합물
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
DE60329375D1 (en) * 2002-03-15 2009-11-05 Univ Wayne State Neue 2-amino-9-((2-hydroxymethyl)cyclopropylidenmethyl)-purine als antivirale mittel
ES2387388T3 (es) * 2002-09-27 2012-09-21 Dainippon Sumitomo Pharma Co., Ltd. Compuesto de adenina y uso del mismo
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
PT2170888E (pt) * 2007-06-29 2015-08-21 Gilead Sciences Inc Purina derivados e sua utilização como moduladores de recetor de tipo toll 7
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CN102272134B (zh) * 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
WO2011049825A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
LT3190113T (lt) 2014-08-15 2021-08-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CR20190087A (es) * 2016-08-29 2019-04-30 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica

Also Published As

Publication number Publication date
CL2019000512A1 (es) 2019-07-12
JP7013467B2 (ja) 2022-01-31
EP3865482A1 (en) 2021-08-18
KR20190039829A (ko) 2019-04-15
AU2022204697A1 (en) 2022-07-21
US20180072730A1 (en) 2018-03-15
KR102459155B1 (ko) 2022-10-28
SG11201901633WA (en) 2019-03-28
CO2019000932A2 (es) 2019-02-08
PE20190476A1 (es) 2019-04-04
EP3504210A1 (en) 2019-07-03
RU2019107957A (ru) 2020-09-29
SG10202010520SA (en) 2020-11-27
HUE053944T2 (hu) 2021-08-30
JP2022050632A (ja) 2022-03-30
RS61752B1 (sr) 2021-05-31
SI3504210T1 (sl) 2021-08-31
UA124270C2 (uk) 2021-08-18
PT3504210T (pt) 2021-04-19
CN109641904B (zh) 2022-01-28
US10752630B2 (en) 2020-08-25
TWI671300B (zh) 2019-09-11
AU2017320742A1 (en) 2019-02-28
ES2867849T3 (es) 2021-10-21
WO2018041763A1 (en) 2018-03-08
JP2019526633A (ja) 2019-09-19
US20190256515A1 (en) 2019-08-22
AU2021204303B2 (en) 2022-05-12
CR20190087A (es) 2019-04-30
IL284255A (en) 2021-07-29
AU2017320742B2 (en) 2021-08-05
MA46038A (fr) 2019-07-03
EP3504210B1 (en) 2021-02-24
US20200385387A1 (en) 2020-12-10
BR112019003519A2 (pt) 2019-05-21
US10233184B2 (en) 2019-03-19
HRP20210621T1 (hr) 2021-05-28
RU2751349C2 (ru) 2021-07-13
DK3504210T3 (da) 2021-04-26
MA46038B1 (fr) 2021-05-31
CA3034148A1 (en) 2018-03-08
NZ750604A (en) 2024-02-23
RU2019107957A3 (es) 2020-12-18
IL284255B (en) 2022-07-01
PL3504210T3 (pl) 2021-07-05
KR20220147702A (ko) 2022-11-03
TW201819382A (zh) 2018-06-01
AU2021204303A1 (en) 2021-07-22
CN109641904A (zh) 2019-04-16
IL264710B (en) 2021-07-29
PH12019500432A1 (en) 2019-10-21
IL293475A (en) 2022-08-01
JP7214900B2 (ja) 2023-01-30
MY197408A (en) 2023-06-16
MX2019002129A (es) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PH12017501258A1 (en) Pyrazine compounds for the treatment of infectious diseases
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
EP4356969A3 (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
TN2017000031A1 (en) Imidazopyridazine compounds
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
EA201990656A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.